News

iQure Pharma Attending JPM Week in San Francisco — January 9-12, 2023

Princeton, NJ, December 14, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, is attending the 41st Annual J.P. Morgan...

iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track

iQure Pharma is one of 25 companies invited to join the NYU Stern School of Business Endless Frontier Labs 2022-2023 cohort dedicated to...

iQure Pharma Secures $600K in Commitments in Early Closing to Research Neuropathic Pain Therapies

Keiretsu Forum and Business Angel Investors Provide Funding to Support Research into Neuropathic Pain Compounds iQ-007 and iQ-008...

iQure Pharma Targets Future with New Board Appointments

Life Sciences industry experts Michael D. Webb and Brian Cain bring extensive expertise in strategic pharmaceutical growth DELAWARE,...

iQure Pharma Will Present at Mid-Atlantic Diamond Venture 2022 Spring Forum

DELAWARE, March, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has been invited to present at the Mid-Atlantic Diamond...

Company signed Agreement with University of Arizona for non-opioid treatment of post-operative pain

Delaware – February 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of novel therapeutics in the area of pain...

iQure Pharma Inc. Secures Private Investment of $100,000

Delaware – September 2020, iQure Pharma Inc. (iQure), a company dedicated to preclinical and early clinical development of new...

iQure Pharma Inc. Secures Additional Investment of $50,000

Delaware – May, 2020, iQure Pharma Inc., a company dedicated to preclinical and early clinical development of new therapeutics, recently...

Chairman Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January

Chairman of the Board, Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January

JPM Week

No Abuse

Promising Compounds